RE:RE:Zenith AACRThanks Bear. It seems progressive in terms of learning. I get the impression that their hypothesis and resulting testing are moving along a path that seems to have one of more underlying hypothesis that seem to be uncovering clues and I sense much more. That gives me reassurance about the knowledge base at Zenith and RVX and, of course, BET inhibition.
I sort of hoped there might be some insight about the health of these very sick patients in terms of surviival but it is very early in the trial.
So the idea of having blood tests (non invasive) for disease progress or regression seems to me to potentially be of significant value. For example if this means that zen3694 (or other variants) could become a tool(s) to assess the progress of the disease, mCRPC, during treatment (i.e. a diagnostic tool) it could have significant potential economic impacts in and of itself.
I hope I am not misinterpreting this but let me know if I am off base.
Toinv